The Use of Mebendazole in COVID-19 Patients: An Observational Retrospective Single Center Study

Table 1

Demographics and clinical variables of the mebendazole treatment group and nonmebendazole treatment group for both inpatients and outpatients.

	Inpatients			Outpatients
	Control	Treatment	value	Control	Treatment	value
N	89	68		91	94
Demographics
Age, year	62 (57, 67)	62 (56, 68)	0.55	48 (41, 54)	40 (34, 48)
Sex, male	55 (61.8)	43 (63.2)	0.87	52 (57.1)	50 (53.2)	0.66
Comorbidity
Diabetes mellitus	7 (7.9)	6 (8.8)	1	4 (4.4)	5 (5.3)	1
Hypertension	7 (7.9)	9 (13.2)	0.30	2 (2.2)	2 (2.1)	1
Vital signs on admission
Temperature (Celsius)	39.1 (38.5, 39.5)	38.6 (38.2, 39.2)		38.8 (38.3, 39.4)	38.5 (38.1, 38.9)
Heart rate	100 (98, 105)	100 (95, 105)	0.65	94 (86, 100)	97 (92, 100)
Respiratory rate	20 (19, 22)	21 (19, 22)	0.61	19 (17, 20)	20 (18, 21)
sO2	90 (89, 92)	85 (83.5, 87.5)		94 (93, 95)	94 (93, 95)	0.85
Lab values
Lymphocyte count	0.9 (0.7, 1.2)	1.1 (0.8, 1.5)		0.9 (0.7, 1.1)	0.8 (0.6, 0.9)
Ferritin	680 (361, 897)	592 (387, 817)	0.63	522 (418, 650)	440 (361, 553)
CRP	64 (49, 82)	48 (36, 95)		37 (27, 48)	25 (18, 36)
D-dimer	1.1 (0.8, 1.8)	1.14 (0.81, 1.71)	0.49	0.9 (0.7, 1.1)	0.8 (0.7, 1.1)	0.60
LDH	648 (487, 754)	669 (527, 780)	0.35	542 (418, 653)	473 (362, 561)
Abnormal LFT	16 (18.0)	14 (20.6)	0.69	6 (6.6)	7 (7.4)	1
Abnormal RFT	15 (16.9)	23 (33.8)		6 (6.6)	6 (6.4)	1
Medications received
Remdesivir	58 (65.2)	35 (51.5)	0.10	0 (0)	0 (0)	1
Steroids	89 (100)	63 (92.6)		20 (22.0)	8 (8.5)
Anticoagulation	89 (100)	68 (100)	1	9 (9.9)	10 (10.6)	1

Continuous variables are presented as medians (interquartile range) and discrete variables are presented as counts (percentage). Continuous variables were compared using the two-sample t-test, and discrete variables were compared using Fisher’s exact test. CRP: C-reactive protein; LFT: liver function tests; RFT: renal function tests.